P/E at 37.36 vs Industry's 36.38: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Premium Reflects Market Confidence

The P/E ratio of Sun Pharmaceutical Industries Ltd at 37.36 is just above the sector average of 36.38, indicating that investors are willing to pay a modest premium for its earnings. This premium suggests a perception of relative strength or growth potential compared to peers within the Pharmaceuticals & Biotechnology industry. However, the difference is not pronounced enough to signal an extreme valuation divergence. The market cap of ₹4,65,711 crores places the company firmly in the large-cap category, reinforcing its status as a key player in the sector.

Given the sector’s current P/E, the premium valuation invites scrutiny on whether the company’s earnings growth and operational metrics justify this slight premium — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating? The four-parameter analysis factors in the valuation premium alongside other performance indicators.

Performance Across Timeframes: Strong Medium-Term Gains Amid Short-Term Fluctuations

Examining the stock’s returns reveals a compelling divergence between short and medium-term performance. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a 14.09% gain, significantly outperforming the Sensex’s 6.01% decline. This outperformance extends to the three-month period, where the stock rose 11.92% compared to the Sensex’s modest 0.96% fall. The year-to-date return of 12.83% also contrasts sharply with the Sensex’s negative 10.16%, underscoring the stock’s resilience in a challenging market environment.

Shorter-term performance is more mixed. The one-month return of 4.20% is positive and better than the Sensex’s 0.70% decline, but the one-week and one-day returns show slight underperformance, with the stock down 0.81% and 0.03% respectively, while the Sensex gained 1.47% and 0.66% in those periods. This suggests some recent profit-taking or consolidation after a strong rally — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Moving Average Configuration: Bullish Across All Key Averages

The technical picture for Sun Pharmaceutical Industries Ltd is notably positive. The stock is trading above all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This alignment indicates a strong upward trend across both short and long-term horizons, signalling sustained buying interest and momentum.

Being above the 200-day moving average is particularly significant as it often marks a long-term bullish trend. The stock is also just 0.61% shy of its 52-week high of ₹1966.75, suggesting it is near peak levels seen in the past year. This technical strength contrasts with the slight short-term underperformance seen in the last week and day, implying that recent dips may be temporary corrections within a broader uptrend.

Sector Context: Pharmaceuticals & Biotechnology Showing Mixed but Stable Results

The Pharmaceuticals & Biotechnology sector has seen four companies declare results recently, with two reporting positive outcomes and two flat, and none negative. This balanced sector performance provides a stable backdrop for Sun Pharmaceutical Industries Ltd to maintain its growth trajectory. The sector’s average P/E of 36.38 reflects moderate valuation levels, consistent with the company’s own premium.

Within this environment, the stock’s outperformance over the Sensex across multiple timeframes highlights its relative strength. The 3-year and 5-year returns of 70.95% and 182.04% respectively, far exceed the Sensex’s 15.54% and 45.62% gains, underscoring a sustained track record of value creation. However, the 10-year return of 140.23% trails the Sensex’s 173.20%, indicating some longer-term relative underperformance — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd. This rating was updated on 8 June 2026, reflecting a reassessment based on the latest financial and technical data. The current Mojo Score stands at 74.0, indicating a positive overall assessment, although the exact rating is not disclosed. This update coincides with the stock’s strong medium-term performance and solid technical positioning, suggesting a shift in the company’s market perception.

The rating change invites investors to consider the implications of the valuation premium and recent momentum — what is the current rating? The comprehensive analysis includes valuation, performance, and technical factors to provide a holistic view.

Conclusion: Data Reflects a Stock with Strong Medium-Term Momentum and Technical Strength

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical company trading at a slight valuation premium relative to its sector. Its one-year and three-month returns significantly outperform the Sensex, supported by a robust technical setup with the stock trading above all major moving averages and near its 52-week high.

While short-term returns show some volatility, the overall momentum remains positive. The sector’s stable results and the company’s reassessed rating from Hold to a more favourable stance underscore the evolving market view. Investors may find value in analysing whether the current premium and momentum justify continued exposure — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today